What's Going On With Hims & Hers Health Stock?
What's Going On With Hims & Hers Health Stock?
CEO Hims & Hers Health Inc (NYSE:HIMS) has seen its stock drop 21% to $25.73 over the past month, driven by regulatory updates from the FDA regarding tirzepatide injection shortages. However, the stock remains up over 200% over the past year, reflecting strong earnings performance.
Hims & HERS Health Inc (紐交所:HIMS) 在過去一個月的股票價格下跌了21%，至25.73美元，這主要是由於FDA關於tirzepatide注射劑短缺的監管更新。然而，該股票在過去一年內上漲了超過200%，反映出強勁的盈利表現。
What To Know: The company reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst expectations of 4 cents. Revenue rose 77% year-over-year to $401.6 million, beating estimates of $382.2 million.
最新消息：該公司在11月報告了令人印象深刻的第三季度業績，每股收益爲32美分，遠超分析師預期的4美分。營業收入同比增長77%，達到40160萬，超出38220萬的預期。
Subscriber growth surged 44%, reaching 2 million, and net income soared to $75.6 million, compared to a net loss of $7.6 million last year. However, gross margins narrowed slightly to 79%, down from 83% a year ago.
訂閱用戶增長了44%，達到200萬，凈利潤飆升至7560萬，而去年則出現了760萬的淨虧損。然而，毛利率略微收窄至79%，低於一年前的83%。
CEO Andrew Dudum highlighted the company's continued momentum, noting its focus on delivering accessible, personalized care. Hims & Hers raised its fiscal 2024 revenue outlook to $1.46-$1.465 billion, indicating confidence in sustained growth.
首席執行官Andrew Dudum強調了公司的持續勢頭，指出其專注於提供可及性強、個性化的醫療服務。Hims & HERS將2024財年的營業收入預期提高至14.6億至14.65億，表明對持續增長的信心。
Investor sentiment has otherwise been tempered over the past month by the FDA's resolution of the tirzepatide shortage, which may pressure demand for compounded alternatives. Despite this, ongoing shortages of other GLP-1 drugs and strong fundamentals could position Hims & Hers for potential long-term success.
但投資者情緒在過去一個月略顯謹慎，原因是FDA解決了tirzepatide短缺的問題，這可能會對複合替代品的需求產生壓力。儘管如此，其他GLP-1藥物的持續短缺以及強勁的基本面可能爲Hims & HERS的潛在長期成功提供支持。
Read Also: US 2025 Recession Odds Plummet: Good News Or Warning Sign?
另請閱讀：美國2025年衰退幾率驟降：好消息還是警告信號？
How To Buy HIMS Stock
如何購買HIMS股票？
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange-traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了前往券商平台購買股票或部分股票外，您還可以通過購買持有該股票的可交易ETF，或者在您的401(k)計劃中配置策略以尋求通過共同基金或其他工具獲取股票來獲取股份。
For example, in Hims & Hers Health's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
例如，在Hims & HERS醫療保健的案例中，它屬於醫療保健板塊。可交易ETF可能會持有許多流動性強和大型公司的股票，這些公司幫助追蹤該板塊，使投資者能夠接觸到該細分市場的趨勢。
According to data from Benzinga Pro, Hims & Hers has a 52-week high of $35.02 and a 52-week low of $8.14.
根據Benzinga Pro的數據，Hims & HERS的52周最高價爲$35.02，52周最低價爲$8.14。
It closed Wednesday down more than 7% at $25.73.
週三收盤時下跌超過7%，報$25.73。
Now Read:
現在閱讀：
- 5 Dead, Nearly 180,000 Evacuated In Los Angeles Wildfires: California Utilities Face Scrutiny
- 洛杉磯野火導致5人死亡，近180,000人撤離：加州公用事業面臨審查
Image: Shutterstock
圖片：Shutterstock
譯文內容由第三人軟體翻譯。
